Piperacillin |
| Catalog No.GD20400 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61477-96-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Piperacillin (12.5 渭g/mL, 24h) inhibits 92% of isolates of Pseudomonas aeruginosa, 82% of Serratia marcescens, 73% of Escherichia coli, 61% of Klebsiella spp, and 42% of Enterobacter spp, most Proteus spp. were extremely susceptible. Piperacillin fails to inhibit the growth of gram-negative bacilli when large inocula were used (minimum inhibitory concentration > 25 渭g/ml) [2].
Piperacillin (100 mg/kg, i.v., 4 times a day, 5 d) in combination with Tazobactam (12.5 mg/kg, i.v., 4 times a day, 5 d) prolongs survival in mice with low inoculum of K. pneumoniae[3].
[1]. Fu KP, et al. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978锛?3(3):358-67.
[2]. Bodey GP, et al. Piperacillin: In Vitro Evaluation. Antimicrob Agents Chemother. 1978锛?4(1):78-87.
[3]. Harada Y, et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2014锛?0(11):O831-9.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *